مباشر

Clinical OMICsCAR T-Cell Therapy Expands Access to Kidney Transplants Endpoints NewsAlnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal FierceBiotechLilly, Boehringer to slash at least $1B each from planned investments in Germany Clinical OMICsGenetically Raised Pulse Pressure Predisposes to Dementia-Linked Death Clinical OMICsEngineered Islets Could Eliminate Need for Immunosuppression in Type 1 Diabetes FierceBiotechUnlocking Unstructured Data with AI for Optimized Protocol Development Endpoints NewsBristol Myers turns focus to AI costs after broad rollout to workers Clinical OMICsNew Tumor Survival Mechanism Revealed in Aggressive ALT Cancers Clinical OMICsVeracyte Launches Test Identifying Breast Cancer Patients Who Don’t Need Chemo Endpoints NewsAxsome pushes back generic entry for narcolepsy drug until 2040 Clinical OMICsNanotube Sensor Provides Chemical Imaging for Earlier Detection of Bladder Cancer Recurrence Endpoints NewsFDA guides pharma on explaining unapproved drugs to payors

FierceBiotech ٣ يونيو ٢٠٢٦

Lilly, Boehringer to slash at least $1B each from planned investments in Germany

In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed...

In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.